(424) 204-0726 info@oncotracker.com
  • Twitter
  • Google
  • Twitter
  • Google
  • About
    • Leadership
    • Scientific Advisory Committee
    • Partners & Collaborators
  • Corporate Relations
    • News & Events
    • Investor Relations
  • Contact
ONCOtracker
  • Home
  • Serum BCMA Biomarker
    • What is BCMA?
    • What is Serum BCMA?
    • What is the Serum BCMA Test?
    • Serum BCMA Test Attributes
  • Testing & Services
    • Immunoassays
    • Pre-clinical Drug Development
    • Biospecimens
    • Work with Us
  • Resources
    • Publications
    • Videos
    • Educational resources
  • Patents & Licensing
    • sBCMA
    • JAK Inhibition
    • Gamma Secretase Inhibition
    • Anti-Sense Drug Constructs
Select Page

Workplace. Computer laptop and mobile phone on a wood office des

May 29, 2020

Oncotracker logo

A leading incubator for cancer treatment innovations with a focus on the diagnosis and treatment of multiple myeloma, other B-cell malignancies and related disorders.

  • Follow
  • Follow
Home
About
   Leadership
   Scientific Advisory Board
   Partners & Collaborators
Resources
   Publications
   Videos
   Educational Resources
Corporate Relations
   News & Events
   Investor Relations
Contact
sBCMA Biomarker
   What is BCMA?
   What is sBCMA?
   What is the sBCMA Test?
   sBCMA Test Attributes
Testing & Services
   Immunoassays
   Pre-clinical Drug Development
   Biospecimens
   Work With Us
Patents & Licensing
  sBCMA   
  JAK Inhibition in Myeloma
  Gamma Secretase
  Anti-Sense Drug Constructs

 

© 2020 ONCOtracker, Inc. All rights reserved.
×

 

James Berenson, MD

Founder and Chief Scientific Officer

Dr. Berenson is the founder and Principal for the James R. Berenson, MD, Inc. dba Berenson Oncology, a unique multi-faceted business entity built around an established and integrated healthcare and biotech family of companies. These consist of:

  • Berenson Oncology: Prolific specialty practice in West Hollywood, CA focused on the treatment of patients with multiple myeloma and related malignancies and conditions. More that 600 patients under his care.
  • Institute for Myeloma & Bone Cancer Research (IMBCR): A mission-driven 501(C)3 non-profit institute dedicated to the discovery of novel treatments in a pre-clinical in vitro and in vivo research laboratory and includes a biobank with long-term clinical samples.
  • ONCOtherapeutics: Recognized targeted CRO leading preclinical research and clinical trials from phase I to IV in community oncology sites throughout the US.
  • ONCOtracker: Emerging incubator for cancer treatment management innovation focused on the diagnosis and treatment of multiple myeloma, other B-cell malignancies and related disorders in pursuit of intellectual property supporting treatment progress & improved outcomes.
  • ONCOcision: A strategic cancer ‘precision medicine’ company that provides individualized guidance for treating multiple cancers.

Dr. Berenson has authored more than 300 peer-reviewed publications and contributed to multiple book chapters. He serves as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section and is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr. Berenson serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society.